AES 2017: TSC Preclinical Consortium Presentation on December 3
If you will be attending the American Epilepsy Society meeting in Washington, DC in December, please join us for TS Alliance Chief Scientific Officer Dr. Steve Roberds’ presentation on the TSC Preclinical Consortium at 10:30 am, Sunday, December 3 in the Discovery Center.
To facilitate the translation of basic and mechanistic research into clinical trials and new treatments for TSC, the TS Alliance created a TSC Preclinical Consortium in collaboration with industry and academia to test the efficacy of candidate therapeutic drugs and advance the best to the clinical stage.
The consortium has been growing rapidly since the first project in August 2016. Thirteen projects have been run or scheduled to date, and we hope to test even more new compounds in the coming year.
Chart last updated October 2017. Results from consortium-initiated “Bucket A” studies are available to all consortium members immediately after study completion. Results of “Bucket B” studies are released to the consortium after an initial escrow period. The results of “Bucket C” studies of proprietary compounds belong entirely to the initiating company.